Clinical and immunological signatures of severe COVID-19 in previously healthy patients with clonal hematopoiesis

Many clinical risk factors for severe COVID-19, such as diabetes, hypertension, and high body mass index have been reported. However, searching for additional risk factors should be continued to predict the progression of severe COVID-19 more accurately. We suppose that clonal hematopoiesis of indeterminate potential (CHIP) can also be regarded as one of risk factors. To identify the influence of CHIP in COVID-19 pathogenesis, we performed single-cell RNA-seq using peripheral blood mononuclear cells (PBMCs) obtained from severe COVID-19 patient with CHIP and integrate the data with other published COVID-19 scRNA seq data (GSE149689). After clustering and annotating cell types, we compare the expression profiles between CHIP vs non-CHIP COVID-19 severe patient. Single-cell RNA sequencing performed with PBMC of 3 COVID-19 patients carrying clonal hematopoesis of intermediate potential, CHIP. nCoV_CHIP_1_1[SW202] and nCoV_CHIP_1_2[SW205] are double sampled from one patient. nCoV_CHIP_1_1[SW202] were sampled in day 17 and nCoV_CHIP_1_2[SW205] were sampled in day 30 after hospitalization. For the control group, COVID-19 severe patient who doesn't carry CHIP were selected from other published COVID-19 scRNA seq data (GSE149689).